库申诺I通过保护肠道屏障和优化肠道微生物群来对抗性结肠炎
Xu-Dong He1,2, Min Li1,2, Xiang-Duo Zuo1,2
1College of Pharmaceutical Science, Yunnan University of Chinese Medicine, Kunming 650500, Yunnan Province, China.
World journal of gastroenterology
|July 18, 2025
概括
库申诺I (KSCI) 通过减少炎症和氧化应激,有效治疗性结肠炎 (UC). 这种天然化合物还可以改善肠道屏障功能,并在UC模型中调节免疫反应.
科学领域:
- 药理学 药理学是指药理学的学科.
- 免疫学 免疫学 免疫学
- 微生物组研究 微生物组研究
背景情况:
- 库希诺尔I (KSCI) 显示出潜在的抗炎和抗氧化特性.
- 它在性结肠炎 (UC) 中的治疗作用和机制需要进一步研究.
研究的目的:
- 阐明KSCI在缓解UC的治疗效果和潜在机制.
- 探索KSCI对UC炎症,氧化应激,肠道屏障,免疫反应和肠道微生物群的影响.
主要方法:
- 网络药理学确定了KSCI对UC的治疗目标.
- 分子对接和模拟验证了KSCI-目标相互作用.
- 通过16S rRNA测序,酸 (DSS) 诱导的UC的小鼠模型评估了KSCI的疗效,抗炎和抗氧化作用,肠道屏障功能,免疫调节和肠道微生物群的变化.
主要成果:
- 网络药理学确定了KSCI的192个潜在的UC目标,与AKT,p38 MAPK,NLRP3,PI3K,FOXO1和TLR4.4等关键目标稳定结合.
- 在DSS诱导的UC小鼠模型中,KSCI的使用改善了结肠长度,体重,并减少了疾病活动.
- KSCI抑制了促炎细胞因子 (IL-1β,IL-6,IL-17,TNF-α),增加了IL-10,抑制了关键信号分子,增强了肠道屏障功能,调节了肠道微生物群,增加了脏T细胞百分比,显示出强大的抗氧化和抗炎作用.
结论:
- 库申诺I通过多方面的机制减轻DSS诱导的UC.
- 这些机制包括调节肠道微生物群,增强肠道屏障完整性,减少炎症和氧化应激,调节免疫反应.
相关概念视频
01:29Drugs for Treatment of Ulcerative Colitis in IBD
239
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
239
01:29Inflammatory Bowel Disease IV: Pharmacological Management
196
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
196
01:24Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
699
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
699
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
271
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
271
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
600
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
600
01:21Drugs for Treatment of Constipation-Predominant IBS
342
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
342